CJC Open最新文献

{"title":"A Novel Nonsense Variant of FBN1 in Marfan Syndrome With Abdominal Aortic Aneurysm and Aortic Root Aneurysm","authors":"Chengkai Hu MD , Li Zhang MD , Anli Jin MD , Tong Yuan MD , Yuchong Zhang MD , Shouji Qiu MD , Wei Guo PhD , Lixin Wang PhD","doi":"10.1016/j.cjco.2025.01.010","DOIUrl":"10.1016/j.cjco.2025.01.010","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 3","pages":"Pages 307-309"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemokine Ligands and Receptors Regulate Macrophage Polarization in Atherosclerosis: A Comprehensive Database Mining Study","authors":"Wanqian Yu MD , Linghua Fu MS , Guangtao Lei MD , Fan Luo MS , Peng Yu MD , Wen Shen MD , Qinghua Wu MS , Pingping Yang MD","doi":"10.1016/j.cjco.2024.11.018","DOIUrl":"10.1016/j.cjco.2024.11.018","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerosis is a systemic disease involving multiple blood vessels and a major cause of cardiovascular disease. Current treatment methods (eg, statins) for atherosclerosis can reduce the risk of cardiovascular diseases effectively, but they are insufficient to completely reverse existing atherosclerosis. Macrophages play a central role in development of atherosclerosis. Chemokines, the main mediators of macrophage chemotaxis, are important in immune and inflammatory responses. The effects of chemokines on mechanisms involved in atherosclerosis are unknown. This study preliminarily investigated these effects and mechanisms via bioinformatics methods.</div></div><div><h3>Methods</h3><div>In this study, data on chemokine ligands and receptors were obtained by mining public databases (the National Center of Biotechnology Information-Gene Expression Omnibus [NCBI-GEO] database, ArrayExpress database, and single-cell RNA sequencing [scRNA-seq] database), and an extensive literature search was performed. The expression levels of chemokines in mouse tissues were analyzed via Metascape software for signalling pathway enrichment, scRNA-seq data for chemokine expression in atherosclerotic plaque progression and regression, and GEO2R data for chemokine expression during macrophage polarization. Ingenuity Pathway Analysis (IPA) software was used to analyze regulatory factors such as transcription factors and microRNAs that are significantly differentially expressed upstream of chemokines in macrophage polarization. Finally, a model of the chemokine regulation of atherosclerosis was established on the basis of these results.</div></div><div><h3>Results</h3><div>There are 5 main findings: (1) In atherosclerosis, chemokines are regulated by transcription factors and microRNAs. (2) The transcription factor STAT1 promotes the polarization of dormant (M0) macrophages into classically activated (M1) macrophages and alternative activated (M2) macrophages by regulating chemokines. The transcription factors STAT1, IRF7 and IRF1 regulate the polarization of M0 macrophages into M2a and M2b macrophages via different chemokines. For example, some transcription factors promote M1 polarization of M0 macrophages through CCL4, but M2 macrophage polarization is regulated via CCL19, CCL5 and CCR7. (3) Transcription factors can promote and inhibit, whereas miRNAs can only inhibit atherosclerosis. (4) CCL4 existed in all 5 different chemokine-regulated macrophage models, whereas CXCL3 only existed in the M2b macrophage transcriptional regulation model, indicating that CXCL3 may promote the M2b type macrophages polarization of M0 macrophages. (5) CCL5 and CCR7 can promote the M2a macrophages and M2b macrophages polarization of M0 macrophages.</div></div><div><h3>Conclusions</h3><div>Atherosclerosis can be treated by regulating chemokines and regulating the polarization of macrophages. The chemokines CCL4, CCL5, CCL8, CCL19, CXCL3, CXCL10, CXCL13, an","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 3","pages":"Pages 310-324"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise Echocardiography of Left Ventricular Diastolic Function in Healthy Subjects: Insights From the RIGHT-NET","authors":"Francesco Ferrara MD, PhD ,&nbsp;Andreina Carbone MD ,&nbsp;Luna Gargani MD, PhD ,&nbsp;Rossana Castaldo PhD ,&nbsp;Paola Argiento MD, PhD ,&nbsp;Gergely Agoston MD ,&nbsp;Rodolfo Citro MD, PhD ,&nbsp;Anna D'Agostino PhD ,&nbsp;Antonello D’Andrea MD, PhD ,&nbsp;Michele D'Alto MD, PhD ,&nbsp;Monica Franzese PhD ,&nbsp;Stefano Ghio MD ,&nbsp;Ekkehard Grünig MD, PhD ,&nbsp;Marco Guazzi MD, PhD ,&nbsp;Jarosław D. Kasprzak MD ,&nbsp;Graziella Lacava MD ,&nbsp;Giuseppe Limongelli MD, PhD ,&nbsp;Alberto Marra MD, PhD ,&nbsp;Matteo Mazzola MD ,&nbsp;Emanuela Passaro MSc ,&nbsp;Robert Naeije MD, PhD","doi":"10.1016/j.cjco.2024.11.015","DOIUrl":"10.1016/j.cjco.2024.11.015","url":null,"abstract":"<div><h3>Background</h3><div>Exercise transthoracic Doppler echocardiography (TTE) is considered suggestive of left ventricular (LV) diastolic dysfunction when the ratio of mitral Doppler E to tissue Doppler e′ waves is &gt;15 with or without a peak tricuspid regurgitation velocity (TRV) &gt;3.4 m/s. However, these measurements may be affected by exercise intensity. The aim of the study was to define the normal limits of LV diastolic function indices during exercise TTE.</div></div><div><h3>Methods</h3><div>One hundred ninety-two healthy adults (47% females, aged 16-76 years) underwent resting and exercise TTE on a semirecumbent cycle ergometer. LV diastolic measurements were acquired at baseline and midlevel exercise (heart rate ≤110 bpm) fusion of E and A waves. TRV was acquired at rest and at peak exercise. The E/e′ ratio was calculated with e′ as the average of septal and lateral measurements.</div></div><div><h3>Results</h3><div>At midlevel exercise, E/e′ increased modestly from 6.3 ± 1.9 to 7.3 ± 2.3 (<em>P</em> &lt; 0.001) as a function of workload and cardiac output (CO), independently of sex and age. The 95th percentile of exercise E/e′ was 11.8. The slope of E/e′/CO was 0.4 ± 1.2/L/min. The slope of TRV/CO was 10.8 ± 11.5 cm/s/L/min. The upper 95% confidence interval of the E/e′/CO and TRV/CO slopes were 0.6/L/min and 13.1 cm/s/L/min, corresponding to an E/e′ of 13.2 and a TRV of 3.4 m/s at a CO of 15 L/min.</div></div><div><h3>Conclusions</h3><div>In healthy adult subjects, E/e′ slightly increased during midlevel exercise. Both E/e′ and TRV are exercise intensity-dependent and would therefore be better expressed as a function of CO for the diagnosis of normal vs abnormal LV diastolic response to exercise.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 3","pages":"Pages 325-333"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-Human Abdominal Aortic Aneurysms Trial with Tricaprin (F-HAAAT): Study Design and Protocol","authors":"Takahito Kamba MD ,&nbsp;Masahiro Yanagawa MD, PhD ,&nbsp;Kazuo Shimamura MD, PhD ,&nbsp;Satoshi Yamaguchi MA ,&nbsp;Kenji Shirakura MSc ,&nbsp;Satomi Okamura MPH ,&nbsp;Yuki Nishimura PhD ,&nbsp;Tomomi Yamada PhD ,&nbsp;Yasushi Sakata MD, PhD, FACC, FESC ,&nbsp;Noriyuki Tomiyama MD, PhD ,&nbsp;Shigeru Miyagawa MD, PhD ,&nbsp;Ken-ichi Hirano MD, PhD ,&nbsp;Nobuhiro Zaima PhD","doi":"10.1016/j.cjco.2024.10.010","DOIUrl":"10.1016/j.cjco.2024.10.010","url":null,"abstract":"<div><div>Approximately 2%-12% of individuals aged &gt; 65 years worldwide are estimated to have an abdominal aortic aneurysm (AAA), with a mortality rate exceeding 60% in rupture cases. The sole preventive intervention against rupture is timely surgery, which requires substantial medical resources, including postoperative complication management. Although numerous randomized clinical trials have been performed, no oral medication effectively treats AAA. Tricaprin, a medium-chain triglyceride with 3 capric acids, is used in dietary therapy for metabolic and neurological disorders. Our group recently reported that tricaprin, unlike other medium-chain triglycerides, showed reverse remodelliing of AAA in a rat model. Determining whether this basic finding could be translated to clinical practice is important. The <strong>F</strong>irst-in-<strong>H</strong>uman <strong>A</strong>bdominal <strong>A</strong>ortic <strong>A</strong>neurysms trial with <strong>T</strong>ricaprin (F-HAAAT) proposes the first-in-human AAA trial to confirm the safety of tricaprin use in patients with small AAA, exploring novel assessment methods to evaluate treatment efficacy. This single-centre, open-label, single-arm study will include 10 patients (aged 50–85 years) with small AAA (30–45 mm in diameter) receiving daily oral tricaprin (1.5–3.0 g/d) for 52 weeks. Primary endpoints include safety evaluation of tricaprin determined by monitoring all adverse events, particularly major adverse cardiovascular events, AAA-related adverse events, and other unpredictable events. Secondary endpoints include parameters to validate tricaprin efficacy by measuring AAA diameter, volume, and Agatston score, and analyzing computed tomography values of the aortic aneurysmal wall. Outcomes of the trial may provide insights into noninvasive methods for indirectly analyzing AAA pathologic characteristics and revealing aneurysmal reverse remodelliing (jRCTs051240036, Japan Registry of Clinical Trials).</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 221-230"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Zero Coronary Artery Calcium Scoring on Downstream Cardiac Testing and Cardiac Outcomes Compared With No Testing","authors":"Ethan Lin MD ,&nbsp;Rea Alonzo MSc ,&nbsp;Jiming Fang PhD ,&nbsp;Anna Chu MHSc ,&nbsp;Levi Elhadad BSc ,&nbsp;Maneesh Sud MD, PhD ,&nbsp;Harindra C. Wijeysundera MD, PhD ,&nbsp;Shalane Basque MSc ,&nbsp;Kate Hanneman MD, MPH ,&nbsp;Elsie Nguyen MD ,&nbsp;Michael E. Farkouh MD, MSc ,&nbsp;Jacob A. Udell MD, MSc ,&nbsp;Idan Roifman MD, MSc","doi":"10.1016/j.cjco.2024.11.009","DOIUrl":"10.1016/j.cjco.2024.11.009","url":null,"abstract":"<div><h3>Background</h3><div>The impact of coronary artery calcium (CAC) scoring on downstream resource utilisation and outcomes remains unclear, especially in those with zero CAC.</div></div><div><h3>Methods</h3><div>Consecutive CAC scores from two academic hospitals in Toronto, Ontario, were linked to population-based databases. Subjects with zero CAC without previous cardiovascular disease were propensity score matched with a non–CAC-tested control group for age, sex, cardiovascular risk factors, and comorbidities. Downstream cardiac testing, acute myocardial infarction, heart failure (HF) hospitalisations, and HF emergency department (ED) visits were compared between the 2 groups.</div></div><div><h3>Results</h3><div>A total of 4884 patients underwent CAC scoring, of whom 2709 had zero CAC (mean 52.9 ± 10.6 years), 55.4% women. At 3.4 years, graded-stress testing (hazard ratio [HR] 1.24, 95% confidence interval [95% CI] 1.14-1.35), stress echocardiography (HR 1.80, 95% CI 1.59-2.05), and cardiac magnetic resonance imaging (HR 3.40, 95% CI 2.55-4.53) use was higher in the zero CAC group, whereas myocardial perfusion scintigraphy (HR 1.08, 95% CI 0.97-1.21) and catheterisation (HR 1.14, 95% CI 0.91-1.44) were similar and percutaneous coronary intervention (HR 0.58, 95% CI 0.35-0.98) and coronary artery bypass grafting (HR 0.14, 95% CI 0.03-0.61) were lower. There was an approximately 5-fold lower rate of myocardial infarction (HR 0.22, 95% CI 0.10-0.51) in the zero CAC group and no difference in HF hospitalisations (HR 1.15, CI 95% 0.53-2.48) or ED admissions (HR 1.21, 95% CI 0.58-2.52).</div></div><div><h3>Conclusions</h3><div>Our results support the utility of zero CAC in limiting interventional cardiovascular procedures while maintaining an association with reduced downstream cardiovascular events.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 211-220"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143158107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline-Referral Criteria and Risk Profiles of Outpatients Referred to a Specialised Heart Failure Clinic","authors":"Isabelle J. Tan HBSc ,&nbsp;Batol Barodi MGA ,&nbsp;Tayler A. Buchan PhD(c) ,&nbsp;Lakshmi Kugathasan PhD ,&nbsp;Michael McDonald MD ,&nbsp;Heather Ross MD, MHSc ,&nbsp;Ana C. Alba MD, PhD","doi":"10.1016/j.cjco.2024.11.006","DOIUrl":"10.1016/j.cjco.2024.11.006","url":null,"abstract":"<div><h3>Background</h3><div>Specialised heart failure (HF) care improves outcomes for patients with HF. To understand the risk profiles of HF outpatients referred to a specialised clinic, we evaluated referral reasons, predicted risk, and the presence of guideline-recommended referral criteria at a large specialised HF clinic.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study including outpatients with HF (≥ 18 years old) referred from November 2021 to November 2022. We calculated 1-year predicted mortality with the use of the Seattle Heart Failure Model (SHFM) and the I-NEED-HELP referral criteria. We compared median SHFM-predicted mortality with referral reasons and the I-NEED-HELP criteria by means of Kruskal-Wallis, Wilcoxon rank-sum, chi-square, and Fisher exact tests.</div></div><div><h3>Results</h3><div>Among 245 consecutive HF outpatients included, median SHFM-predicted 1-year mortality was 4% (interquartile range [IQR] 2%-8%). Reasons for referral included evaluation for advanced therapies (29%), medication optimisation (23%), diagnostic evaluation (19%), post-hospitalisation/emergency department visit (14%), ongoing HF management (12%), patient request (2%), and transition to adult care (1%). The median SHFM-predicted 1-year mortality did not differ significantly by referral reason (<em>P</em> = 0.11) but differed significantly among patients meeting any (5%, IQR 3%-9%) vs no (3%, IQR 2%-5%) I-NEED-HELP criteria (<em>P</em> &lt; 0.001). Across referral reasons, the presence of any I-NEED-HELP criteria differed significantly (<em>P</em> &lt; 0.001); most patients referred for advanced therapies evaluation (96%) and diagnostic evaluation (94%) met at least 1 criterion.</div></div><div><h3>Conclusions</h3><div>Patients referred to a specialised HF clinic have a wide risk range. The difference in predicted mortality among patients meeting any vs no I-NEED-HELP criteria appears clinically insignificant. Incorporating model-predicted risk at the time of referral can guide triage and patient prioritisation.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 127-136"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transapical Transcatheter Aortic Valve Implantation with the J-Valve System in Aortic Regurgitation","authors":"Pengxiong Zhu MD ,&nbsp;Jinping Li MD ,&nbsp;Bangde Xue MD ,&nbsp;Jing Huang MD ,&nbsp;Yun Ling M.Med ,&nbsp;Qi Zhang MD ,&nbsp;Jun Liu MD","doi":"10.1016/j.cjco.2024.10.009","DOIUrl":"10.1016/j.cjco.2024.10.009","url":null,"abstract":"<div><h3>Background</h3><div>Aortic regurgitation (AR) is a condition associated with significant morbidity and mortality, particularly in severe cases. The J-Valve system, next-generation transcatheter heart valve, may overcome the procedural challenges associated with treating pure AR. This study reported the outcome of use of the J-Valve for treatment of AR.</div></div><div><h3>Methods</h3><div>This study observed 47 patients undergoing transcatheter aortic valve implantation (TAVI) with the J-Valve system. Diagnostic evaluation included transthoracic echocardiography and multislice computed tomography to assess AR severity and anatomic characteristics essential for TAVI. Follow-up evaluations were conducted at various intervals postoperation to evaluate outcomes.</div></div><div><h3>Results</h3><div>The patients had a mean age of 73.0 ± 9.0 years and a median ejection fraction of 58.0% (interquartile range, 45.0%–64.0%). The median European System for Cardiac Operative Risk Evaluation (EuroSCORE II) was 3.0% (interquartile range, 2.0%–6.7%). The procedural success rate was 100%, with no need for a second valve implantation or conversion to sternotomy. Short-term outcomes showed significant improvements in the New York Heart Association functional classification (<em>P</em> &lt; 0.001), the left ventricular ejection fraction (<em>P</em> = 0.009), and the left ventricular end-diastolic diameter (<em>P</em> &lt; 0.001). A singular case of valve migration and severe perivalvular leakage due to Behçet's disease prompted a revised approach incorporating immunomodulation therapy.</div></div><div><h3>Conclusions</h3><div>TAVI with the J-Valve system presents a viable alternative for managing severe AR, demonstrating high procedural success and substantial clinical improvement. However, the case of valve migration due to Behçet's disease highlights the need for careful preoperative screening and consideration of autoimmune disorders in differential diagnoses.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 145-152"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Tamponade Complicating Transcatheter Aortic Valve Replacement: Insights From a Single-Center Registry","authors":"Ibrahim Naoum MD,&nbsp;Amnon Eitan MD,&nbsp;Hussein Sliman MD,&nbsp;Avinoam Shiran MD,&nbsp;Salim Adawi MD,&nbsp;Ihab Asmer,&nbsp;Keren Zissman MD,&nbsp;Ronen Jaffe MD","doi":"10.1016/j.cjco.2024.11.005","DOIUrl":"10.1016/j.cjco.2024.11.005","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac tamponade complicating transcatheter aortic valve replacement (TAVR) typically results from right ventricular (RV) injury induced by a pacemaker electrode, left ventricular (LV) injury induced by guidewires and catheters used during the procedure, and rupture of the aortic annulus during valve implantation.</div></div><div><h3>Methods</h3><div>We retrospectively analysed our institutional TAVR database to gain mechanistic insights relating to this complication.</div></div><div><h3>Results</h3><div>A total of 1247 TAVR procedures were performed from 2010 to 2024. Cardiac tamponade complicated 21 (1.7%) of these procedures. There was a nonsignificant reduction in occurrence of tamponade (1.9% among the first 623 cases vs 1.4% among the subsequent 624 cases; <em>P</em> = 0.44). Tamponade was caused by LV perforation in 10 cases (48%), pacemaker-induced RV perforation in 8 cases (38%), and annular rupture in 3 cases (14%). We identified 2 mechanisms causing LV perforation: The stiff guidewire used for valve delivery caused myocardial injury in 7 cases, and in the other 3 cases, LV perforation occurred before insertion of the stiff guidewire and was attributed to insertion of soft guidewires. No additional such cases occurred after implementation of a protocol for meticulous guidewire insertion into the LV. Pericardiocentesis was performed with tamponade in 20 patients and with cardiac surgery in 13. Nine patients (43%) died during the index hospitalisation. Mortality did not differ between cases with RV perforation and left-side perforation.</div></div><div><h3>Conclusions</h3><div>Periprocedural cardiac tamponade during TAVR may be caused by various mechanisms. Careful guidewire manipulation may decrease occurrence of LV perforation.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 153-160"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing ECG Lead Subsets for Heart Arrhythmia/ECG Pattern Classification: Convolutional Neural Networks and Random Forest","authors":"Serhii Reznichenko MS ,&nbsp;John Whitaker MD, PhD ,&nbsp;Zixuan Ni PhD ,&nbsp;Shijie Zhou PhD","doi":"10.1016/j.cjco.2024.10.012","DOIUrl":"10.1016/j.cjco.2024.10.012","url":null,"abstract":"<div><h3>Background</h3><div>Despite the growth in popularity of deep learning (DL), limited research has compared the performance of DL and conventional machine learning (CML) methods in heart arrhythmia/electrocardiography (ECG) pattern classification. In addition, the classification of heart arrhythmias/ECG patterns is often dependent on specific ECG leads for accurate classification, and it remains unknown how DL and CML methods perform on reduced subsets of ECG leads. In this study, we sought to assess the accuracy of convolutional neural network (CNN) and random forest (RF) models for classifying arrhythmias/ECG patterns using reduced ECG lead subsets representing DL and CML methods.</div></div><div><h3>Methods</h3><div>We used a public data set from the PhysioNet Cardiology Challenge 2020. For the DL method, we trained a CNN classifier extracting features for each ECG lead, which were then used in a feedforward neural network. We used a random forest classifier with manually extracted features for the CML method. Optimal ECG lead subsets were identified by means of recursive feature elimination for both methods.</div></div><div><h3>Results</h3><div>The CML method required 19% more leads (equating to ∼ 2 leads) compared with the DL method. Four common leads (I, II, V5, V6) were identified in each of the subsets of ECG leads using the CML method, and no common leads were consistently present for the DL method. The average macro F1 scores were 0.761 for the DL and 0.759 for the CML.</div></div><div><h3>Conclusions</h3><div>Optimal ECG lead subsets provide classification accuracy similar to that using all 12 leads across DL and CML methods. The DL method achieved slightly higher classification accuracy on larger data sets and required fewer ECG leads compared with the CML method.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 176-186"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling Mitochondrial Cardiomyopathy: The Crucial Role of Multiparametric Cardiac Magnetic Resonance","authors":"Rita dos Reis Santos MD ,&nbsp;Joana Certo Pereira MD ,&nbsp;Pedro Lopes MD ,&nbsp;Pedro Freitas MD ,&nbsp;Marisa Trabulo MD ,&nbsp;João Abecasis MD, PhD","doi":"10.1016/j.cjco.2024.11.008","DOIUrl":"10.1016/j.cjco.2024.11.008","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 2","pages":"Pages 137-140"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143157994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}